{
  "source": "PA-HCR-Tobacco-Cessation.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2025 P 2045-17\nProgram Prior Authorization/HCR - Tobacco Cessation - Health Care Reform\nMedication Varenicline (generic Chantix®), Nicotrol Inhaler® (nicotine inhalation\nsystem), and Nicotrol NS® (nicotine nasal spray)\nP&T Approval Date 10/2014, 2/2015, 10/2015, 5/2016, 11/2016, 5/2017, 5/2018, 9/2018,\n11/2018, 5/2019, 12/2019, 5/2020, 3/2021, 8/2021, 9/2022, 11/2023,\n3/2025\nEffective Date 6/1/2025\n1. Background:\nTobacco cessation therapies are more likely to be successful for patients who are motivated\nto stop tobacco use and who are provided additional advice and support. Patients should be\nprovided with appropriate educational materials and counseling to support the quit attempt.\nThe patient should set a quit date.\nThis program is designed to meet Health Care Reform requirements for tobacco cessation\ncoverage at zero dollar cost share.\n2. Coverage Criteria*:\nA. Varenicline (generic Chantix)\n1. Varenicline will be approved based on all of the following criteria:\na. Patient is 18 years of age or oldera\n-AND-\nb. Treatment is being requested for tobacco cessation\n-AND-\nc. History of failure, contraindication, or intolerance to one of the following:\n(1) Nicotine replacement patches OTC (e.g. Nicoderm CQ®-OTC)\n(2) Nicotine gum OTC (e.g. Nicorette® gum- OTC)\n(3) Nicotine lozenge or mini-lozenge OTC (e.g. Nicorette® lozenge-OTC)\n-AND-\nd. History of failure, contraindication, or intolerance to bupropion\n-AND-\n© 2025 UnitedHealthcare Services Inc.\n1\ne. Treatment duration has not exceeded a total of 2 (3 month) cycles of Tobacco Cessation\nTherapy per 12 month periodb\nAuthorization will be issued for zero copay with deductible bypass for 3 months per\n12 month period. Maximum coverage is 2 (3 month) cycles of Tobacco Cessation\nTherapy per 12 month periodb\nB. Nicotrol NS or Nicotrol Inhaler\n1. Nicotrol NS or Nicotrol Inhaler will be approved based on all of the following criteria:\na. Patient is 18 years of age",
    "acco Cessation\nTherapy per 12 month periodb\nB. Nicotrol NS or Nicotrol Inhaler\n1. Nicotrol NS or Nicotrol Inhaler will be approved based on all of the following criteria:\na. Patient is 18 years of age or oldera\n-AND-\nb. Treatment is being requested for tobacco cessation\n-AND-\nc. History of failure, contraindication, or intolerance to one of the following:\n(1) Nicotine replacement patches OTC (e.g.Nicoderm CQ-OTC)\n(2) Nicotine gum OTC (eg Nicorette gum- OTC)\n(3) Nicotine lozenge or mini-lozenge OTC (e.g. Nicorette lozenge-OTC)\n-AND-\nd. History of failure, contraindication, or intolerance to bupropion\n-AND-\ne. Treatment duration has not exceeded a total of 2 (3 month) cycles of Tobacco Cessation\nTherapy per 12 month periodb\nAuthorization will be issued for zero copay with deductible bypass for 3 months per\n12 month period. Maximum coverage is 2 (3 month) cycles of Tobacco Cessation\nTherapy per 12 month periodb\n* Review not required for plans sitused in the state of California, Colorado, Illinois, New York or\nWest Virginia\na Age is 15 years or older for plans sitused in the state Oregon\nb Pharmacist review is required for more than 2 cycles per 12 month period. One cycle is defined as\nmore than 1 month of medication. If only one month of medication is filled, 2 additional cycles of\nmedication may be authorized in the 12 month period\n© 2025 UnitedHealthcare Services Inc.\n2\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-\nauthorization based solely on previous claim/medication history, diagnosis codes (ICD-10)\nand/or claim logic. Use of automated approval and re-approval processes varies by program\nand/or therapeutic class.\n• Supply limits may be in place.\n4. References:\n1. Nicotrol NS [package insert]. New York, NY: Pharmacia and Upjohn: June 2024.\n2. Nicotrol Inhaler [package insert]. New York, NY: Pharmacia and Upjohn; July 2024.\n4. Chantix [package insert]. New York, NY: Pfizer, Inc.; February 2019.\n5. US",
    " NY: Pharmacia and Upjohn: June 2024.\n2. Nicotrol Inhaler [package insert]. New York, NY: Pharmacia and Upjohn; July 2024.\n4. Chantix [package insert]. New York, NY: Pfizer, Inc.; February 2019.\n5. US Department of Health and Human Services. Clinical practice guideline for treating\ntobacco use and dependence: 2008 Update. Washington, DC: US Department of Health and\nHuman Services;.Am J Prev Med 2008;35(2)\nProgram Prior Authorization/-HCR- Tobacco Cessation- Health Care Reform\nChange Control\nDate Change\n10/2014 New program\n2/2015 Policy renamed from Smoking Cessation to Tobacco Cessation.\nAdministrative changes.\n10/2015 Annual review. Updated references. Updated criteria for Chantix to\nallow for coverage if currently using bupropion for an indication other\nthan tobacco cessation.\n1/2016 Administrative update for California requirements.\n5/2016 Update for Massachusetts and Oregon requirements. Medication names\nupdated for OTC products to generics.\n11/2016 Update for Indiana, Louisiana and New Mexico requirements.\n5/2017 Removed Habitrol from first line options - product no longer available.\n5/2018 Annual Review. Updated references.\n9/2018 Removed Commit and Thrive as examples of therapy. Brand names off\nthe market. Revised language around concomitant use and tobacco\ncessation requirements.\n11/2018 Add West Virginia and California to bypass of prior authorization\nrequirements.\n5/2019 Removed PA criteria for bupropion SR, and OTC NRT. Removed\ncombination criteria for Chantix and Nicotrol NS. Removed counseling\nrequirement. Revised footnotes.\n12/2019 Added Colorado and New York to bypass of prior authorization\nrequirements.\n5/2020 Updated references.\n3/2021 Added criteria for treatment duration not to exceed 2 (3 month) cycles\nof Tobacco Cessation Therapy per 12 month period.\n8/2021 Updated to reflect generic launch of Chantix\n9/2022 Annual review. No changes.\n11/2023 Annual review. No changes.\n© 2025 UnitedHealthcare Services Inc.\n3\n3/2025 Removed reference to Zyban due",
    ".\n8/2021 Updated to reflect generic launch of Chantix\n9/2022 Annual review. No changes.\n11/2023 Annual review. No changes.\n© 2025 UnitedHealthcare Services Inc.\n3\n3/2025 Removed reference to Zyban due to product becoming obsolete.\nUpdated references.\n© 2025 UnitedHealthcare Services Inc.\n4"
  ]
}